These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6784914)

  • 1. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy.
    Liesmann J; Belt R; Haas C; Hoogstraten B
    Cancer; 1981 Apr; 47(8):1959-62. PubMed ID: 6784914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of ICRF-187 by 48-hour continuous infusion.
    Koeller JM; Earhart RH; Davis HL
    Cancer Treat Rep; 1981; 65(5-6):459-63. PubMed ID: 6786740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.
    Vogel CL; Gorowski E; Davila E; Eisenberger M; Kosinski J; Agarwal RP; Savaraj N
    Invest New Drugs; 1987; 5(2):187-98. PubMed ID: 3115912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
    Wheeler RH; Bricker LJ; Natale RB; Baker SR
    Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of ICRF-187 using a daily for 3 days schedule.
    Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
    Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
    Dyment PG; Starling KA; Land VJ; Cangir A; Komp DM; Sexauer CL
    Cancer Treat Rep; 1979 Aug; 63(8):1397-8. PubMed ID: 476712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
    DeSimone PA; Greco FA; Omura GA; Bartolucci A
    Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.
    Conroy JF; Lewis GC; Blessing JA; Mangan C; Hatch K; Wilbanks G
    Am J Clin Oncol; 1984 Apr; 7(2):131-3. PubMed ID: 6702716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of ICRF-187 in children with solid tumors and acute leukemia.
    Vats T; Kamen B; Krischer JP
    Invest New Drugs; 1991 Nov; 9(4):333-7. PubMed ID: 1804808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
    Corder MP; McFadden DB; Bell SJ
    Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
    Bonomi P; Yordan E; Blessing JA
    Am J Clin Oncol; 1988 Feb; 11(1):1-2. PubMed ID: 3277372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of ICRF-159 in refractory metastatic breast cancer.
    Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
    Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
    O'Connell MJ; Begg CB; Silverstein MN; Glick JH; Oken MM
    Cancer Treat Rep; 1980; 64(12):1355-8. PubMed ID: 7008938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
    Vogl SE; Lanham R; Kaplan BH
    Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
    Paul AR; Catalano RB; Engstrom PF
    Cancer Treat Rep; 1980; 64(10-11):1047-9. PubMed ID: 7006805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Conroy J; Hatch K; DiSaia PJ; Twiggs LB
    Am J Clin Oncol; 1986 Feb; 9(1):15-7. PubMed ID: 3953488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.
    Holcenberg JS; Tutsch KD; Earhart RH; Ungerleider RS; Kamen BA; Pratt CB; Gribble TJ; Glaubiger DL
    Cancer Treat Rep; 1986 Jun; 70(6):703-9. PubMed ID: 3089595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
    Olweny CL; Sikyewunda W; Otim D
    Oncology; 1980; 37(3):174-6. PubMed ID: 7360489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.